A recent study reveals that patients who stop using new weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass far faster than those who stop conventional diet and exercise regimens.
Findings released in a major medical journal shows that while overweight individuals frequently drop about a fifth of their total mass while undergoing treatment, the weight comes back at an estimated rate of nearly a kilo each month after stopping.
"People purchasing such treatments must be cognizant of the potential of rapid weight regain when the treatment is stopped," stated expert Dr. Susan Jebb.
Such speed of regain suggests a reversion to pre-treatment weight in about one and a half years.
Weighing Treatments
The study, which examined 37 of studies involving over 9,000 of participants, contrasted the effects of the injectable medications with other pills.
Scientists point out that people who lose weight through diet and exercise usually see a more gradual weight regain—perhaps 0.1 kg a month—post-intervention.
The Reason for the Rapid Rebound
Nutrition scientists believe the mechanism of the injections accounts for the amplified regain.
GLP-1 drugs copy a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.
"Long-term administration of GLP-1 concentrations several times higher than the body's typical production might result in the system to generate a reduced amount of its own natural hormone, and could lessen sensitivity to its effects," noted Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this hormone supplement leads to appetite is no longer kept in check, making excessive eating much more probable."
An Ongoing Issue?
Health authorities recommend the injections for people with obesity-related medical conditions, alongside prescribed lifestyle changes.
Many experts contend that, given the likelihood of weight regain, the treatment might need to be ongoing.
This view is supported by pharmaceutical companies, who note that the findings "highlight the chronic character of obesity," similar to managing diseases like high blood pressure.
Patient Accounts
Users who have discontinued the medication explain a sudden resurgence of cravings.
"It felt as if something that goes on and I was suddenly extremely hungry," recalled an individual.
The struggle is compounded if patients have not adopted sustainable lifestyle or habit modifications during therapy.
Widespread Interest
Survey data show that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with desire being substantial.
- Adoption is greater among females compared to men.
- The middle-aged age group shows the greatest usage rates.
- A large proportion obtain the medications through private healthcare rather than public health services.
Ultimately, clinicians caution that while GLP-1 drugs are effective tools for shedding pounds, they are not a standalone fix and lasting health benefits relies on integrated lifestyle management.
